Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis

BACKGROUND: Approximately half of tumor cell lines are resistant to the tumor-selective apoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand (Apo22L/TRAIL). Previously, we showed that combining Apo2L/TRAIL with sorafenib, a multikinase inhibitor, results in dramatic efficacy...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Abdulghani, Junaid, Allen, Joshua E., Dicker, David T., Liu, Yingqiu Yvette, Goldenberg, David, Smith, Charles D., Humphreys, Robin, El-Deiry, Wafik S.
格式: Artigo
語言:Inglês
出版: Public Library of Science 2013
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3784419/
https://ncbi.nlm.nih.gov/pubmed/24086526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0075414
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍